USNA
Company Description
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 925.26M | 854.50M | 921.01M | 998.60M | 1.19B | 1.13B | 1.06B | 1.19B | 1.05B | 1.01B | 918.50M | 790.47M |
| Net Income | 10.76M | 42.03M | 63.79M | 69.35M | 116.50M | 124.66M | 100.53M | 126.22M | 62.53M | 100.04M | 94.67M | 76.64M |
| EPS | 0.58 | 2.20 | 3.33 | 3.60 | 5.78 | 5.89 | 4.44 | 5.36 | 2.60 | 4.09 | 3.71 | 3.11 |
| Free Cash Flow | 8.53M | 50.92M | 56.15M | 93.50M | 108.46M | 145.31M | 110.16M | 140.69M | 110.56M | 104.33M | 87.74M | 84.76M |
| FCF / Share | 0.46 | 2.67 | 2.92 | 4.86 | 5.38 | 6.91 | 4.87 | 5.97 | 4.60 | 4.26 | 3.51 | 3.35 |
| Operating CF | 22.35M | 60.99M | 70.64M | 103.90M | 121.23M | 160.40M | 126.73M | 152.12M | 123.78M | 137.03M | 111.47M | 105.19M |
| Total Assets | 742.91M | 748.19M | 632.76M | 596.55M | 577.74M | 640.89M | 516.93M | 554.46M | 519.27M | 470.64M | 423.24M | 350.58M |
| Total Debt | 14.00M | 39.20M | 13.21M | 13.78M | 17.30M | 21.47M | 25.60M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 158.38M | 181.77M | 330.42M | 288.42M | 239.83M | 312.88M | 234.83M | 214.33M | 247.13M | 175.77M | 143.21M | 111.13M |
| Book Value | 533.10M | 532.11M | 497.20M | 434.47M | 395.12M | 441.65M | 351.71M | 391.15M | 363.21M | 325.29M | 280.85M | 230.16M |
| Return on Equity | 0.02 | 0.08 | 0.13 | 0.16 | 0.29 | 0.28 | 0.29 | 0.32 | 0.17 | 0.31 | 0.34 | 0.33 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 250.22M | 226.20M | 213.67M | 235.85M | 249.54M | 213.61M | 200.22M | 212.87M | 227.80M | 221.08M | 213.37M | 238.20M |
| Net Income | 7.51M | (1.77M) | (6.52M) | 9.65M | 9.40M | 4.48M | 10.61M | 10.43M | 16.54M | 16.77M | 11.35M | 17.29M |
| EPS | 0.41 | -0.10 | -0.36 | 0.52 | 0.49 | 0.23 | 0.56 | 0.55 | 0.86 | 0.88 | 0.59 | 0.90 |
| Free Cash Flow | 7.11M | (6.18M) | (5.16M) | 7.19M | 12.68M | 3.98M | 27.14M | 5.32M | 14.48M | 18.70M | 20.78M | 5.94M |
| FCF / Share | 0.39 | -0.34 | -0.28 | 0.39 | 0.67 | 0.21 | 1.42 | 0.28 | 0.76 | 0.98 | 1.08 | 0.31 |
| Operating CF | 9.76M | (3.39M) | (1.96M) | 12.22M | 15.48M | 5.79M | 29.53M | 7.99M | 17.68M | 26.02M | 22.23M | 9.55M |
| Total Assets | 738.97M | 742.91M | 726.59M | 734.53M | 746.60M | 748.19M | 671.31M | 631.42M | 629.27M | 632.76M | 601.15M | 602.68M |
| Total Debt | 14.00M | 14.00M | 0 | 0 | 23.00M | 39.20M | 0 | 0 | 1.32M | 13.21M | 0 | 0 |
| Cash & Equiv | 162.75M | 158.38M | 145.35M | 151.34M | 179.61M | 181.77M | 364.89M | 332.42M | 328.34M | 330.42M | 307.08M | 300.18M |
| Book Value | 543.55M | 533.10M | 528.07M | 531.06M | 529.76M | 532.11M | 533.09M | 512.21M | 499.99M | 497.20M | 470.39M | 468.82M |
| Return on Equity | 0.01 | -0.00 | -0.01 | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.04 |